Shopping Cart
- Remove All
- Your shopping cart is currently empty
ZG-2291 is a selective inhibitor targeting FIH (hypoxia-inducible factor inhibitor) with oral activity. It selectively inhibits FIH by binding to it and inducing a conformational flip in a catalytically crucial tyrosine, without affecting other 2OG oxidases of the JmjC subfamily. ZG-2291 promotes thermogenesis and ameliorates obesity symptoms and metabolic dysfunctions in ob/ob mice. This compound holds promise for research in the field of obesity-related diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | ZG-2291 is a selective inhibitor targeting FIH (hypoxia-inducible factor inhibitor) with oral activity. It selectively inhibits FIH by binding to it and inducing a conformational flip in a catalytically crucial tyrosine, without affecting other 2OG oxidases of the JmjC subfamily. ZG-2291 promotes thermogenesis and ameliorates obesity symptoms and metabolic dysfunctions in ob/ob mice. This compound holds promise for research in the field of obesity-related diseases. |
In vitro | ZG-2291 (5 or 20 μM, 48 hours) acts as an active cell-penetrating FIH inhibitor in Hep3B cells. Additionally, ZG-2291 enhances thermogenesis and improves lipid accumulation in 3T3-L1 derived adipocytes. |
In vivo | Administered every other day for 30 days at a dosage of 10 mg/kg via intraperitoneal injection, ZG-2291 effectively combats obesity symptoms in ob/ob mice and significantly ameliorates associated metabolic dysfunctions. |
Molecular Weight | 373.75 |
Formula | C17H12ClN3O5 |
Cas No. | 2962103-40-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.